196 related articles for article (PubMed ID: 20122806)
1. Esophagogastric cancer: targeted agents.
Ku GY; Ilson DH
Cancer Treat Rev; 2010 May; 36(3):235-48. PubMed ID: 20122806
[TBL] [Abstract][Full Text] [Related]
2. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapies in advanced gastric cancer.
Janjigian YY; Shah MA
Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan S; Prabhakar D; Sharma N
Anticancer Res; 2013 Oct; 33(10):4139-55. PubMed ID: 24122977
[TBL] [Abstract][Full Text] [Related]
5. Emerging tyrosine kinase inhibitors for esophageal cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2013 Jun; 18(2):219-30. PubMed ID: 23725567
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies with chemoradiation in esophageal cancer: development and future directions.
Hong TS; Wo JY; Kwak EL
Semin Radiat Oncol; 2013 Jan; 23(1):31-7. PubMed ID: 23207045
[TBL] [Abstract][Full Text] [Related]
7. Targeted agents and esophageal cancer--the next step?
Aklilu M; Ilson DH
Semin Radiat Oncol; 2007 Jan; 17(1):62-9. PubMed ID: 17185199
[TBL] [Abstract][Full Text] [Related]
8. Emerging mAbs for the treatment of esophagogastric cancer.
Ku GY; Ilson DH
Expert Opin Emerg Drugs; 2015 Mar; 20(1):63-74. PubMed ID: 25483267
[TBL] [Abstract][Full Text] [Related]
9. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
Varadhachary G; Ajani JA
Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
[TBL] [Abstract][Full Text] [Related]
10. Novel targets in gastric and esophageal cancer.
Valverde CM; Macarulla T; Casado E; Ramos FJ; Martinelli E; Tabernero J
Crit Rev Oncol Hematol; 2006 Aug; 59(2):128-38. PubMed ID: 16829119
[TBL] [Abstract][Full Text] [Related]
11. Novel investigational drugs for gastric cancer.
Vecchione L; Orditura M; Ciardiello F; De Vita F
Expert Opin Investig Drugs; 2009 Jul; 18(7):945-55. PubMed ID: 19466878
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
Arnold D; Peinert S; Voigt W; Schmoll HJ
Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for advanced esophagogastric adenocarcinoma.
Kordes S; Cats A; Meijer SL; van Laarhoven HW
Crit Rev Oncol Hematol; 2014 Apr; 90(1):68-76. PubMed ID: 24183912
[TBL] [Abstract][Full Text] [Related]
14. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis.
Lee W; Patel JH; Lockhart AC
Expert Opin Investig Drugs; 2009 Sep; 18(9):1351-64. PubMed ID: 19642951
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants in targeted therapy for esophageal adenocarcinoma.
Vallböhmer D; Peters JH; Kuramochi H; Oh D; Yang D; Shimizu D; DeMeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; Danenberg PV; DeMeester TR
Arch Surg; 2006 May; 141(5):476-81; discussion 481-2. PubMed ID: 16702519
[TBL] [Abstract][Full Text] [Related]
16. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.
Capurso G; Fazio N; Festa S; Panzuto F; De Braud F; Delle Fave G
Crit Rev Oncol Hematol; 2009 Nov; 72(2):110-24. PubMed ID: 19249226
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for esophageal cancer.
Homs MY; Voest EE; Siersema PD
Expert Opin Emerg Drugs; 2009 Jun; 14(2):329-39. PubMed ID: 19453287
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
20. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Johnston SR
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]